The proceedings of brain metastases from lung cancer

被引:0
作者
Zhao, Hang [2 ]
Li, Guijie [3 ]
Yu, Chunlei [4 ]
An, Zhe [1 ]
机构
[1] Jilin Univ, Dept Cardiol, China Japan Union Hosp, Changchun 130033, Peoples R China
[2] Jilin Univ, China Japan Union Hosp, Dept Neurosurg, Changchun 130033, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Otorhinolaryngol Head & Neck Surg, Changchun 130033, Peoples R China
[4] Jilin Univ, FAW Gen Hosp, Dept Neurosurg, Changchun 130011, Peoples R China
关键词
lung cancer; brain metastases; molecular targeting treatment; chemotherapeutics; CHEMOTHERAPY; CRIZOTINIB; THERAPY;
D O I
10.1515/biol-2016-2016
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Brain tumors include primary tumors of various intracranial tissue and secondary intracranial tumors that transferred from other parts of the body. Secondary intracranial tumors are especially prevalent in patients with lung cancer. The mechanisms of lung cancer with brain metastases are complicated, they are affected by a variety of factors. Thus, identifying the mechanisms of lung cancer with brain metastases will have far-reaching meanings both for clinic pharmacy research and for a better quality of life for patients; Brain metastases from lung cancer represent a prevalent and challenging clinical dilemma, and some research suggests that the outcomes and characteristics of brain metastases that result from lung cancer primary sites are perhaps different than those from other primary sites, therefore increasing the difficulty of clinical treatment. Despite steady research developments during recent years, the survival rates remain poor. The mechanisms and therapeutic options for treating brain metastases arising from lung cancer are review in this article.
引用
收藏
页码:116 / 121
页数:6
相关论文
共 45 条
[1]  
Alsidawi S., 2014, AM J THER
[2]  
[Anonymous], 2002, BAYES LIB DIAGNOSTIC
[3]   A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis [J].
Auchter, RM ;
Lamond, JP ;
Alexander, E ;
Buatti, JM ;
Chappell, R ;
Friedman, WA ;
Kinsella, TJ ;
Levin, AB ;
Noyes, WR ;
Schultz, CJ ;
Loeffler, JS ;
Mehta, MP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (01) :27-35
[4]   Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) [J].
Barlesi, F. ;
Gervais, R. ;
Lena, H. ;
Hureaux, J. ;
Berard, H. ;
Paillotin, D. ;
Bota, S. ;
Monnet, I. ;
Chajara, A. ;
Robinet, G. .
ANNALS OF ONCOLOGY, 2011, 22 (11) :2466-2470
[5]   Erlotinib for the treatment of brain metastases in non-small cell lung cancer [J].
Brower, Jeffrey V. ;
Robins, H. Ian .
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) :1013-1021
[6]  
Chen YH, 2014, BRAIN METASTASES FROM PRIMARY TUMORS, VOL 1: EPIDEMIOLOGY, BIOLOGY, AND THERAPY, P213, DOI 10.1016/B978-0-12-800896-6.00019-X
[7]   THE ROLE OF RADIATION-THERAPY IN THE TREATMENT OF BRAIN METASTASES [J].
COIA, LR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (01) :229-238
[8]   Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer [J].
Ebert, BL ;
Niemierko, E ;
Shaffer, K ;
Salgia, R .
ONCOLOGIST, 2003, 8 (01) :69-75
[9]   The treatment of brain metastases from lung cancer [J].
Ellis, R ;
Gregor, A .
LUNG CANCER, 1998, 20 (02) :81-84
[10]  
Gang C., 2009, EUROPEAN J CARDIOTHO, V37, P546